CGON Stock Forecast & Price Target

CG Oncology is positioned for growth with the upcoming clinical trial and expansion into other types of bladder cancer. The potential risk reduction and positive data from previous trials, along with the company's manufacturing capabilities and conservative pricing, suggest strong potential for commercial success and peak revenues of $1.4B. However, concerns about competition and FDA approval timing should be monitored closely, especially with the looming presence of competitor Protara Therapeutics.

CG Oncology is pursuing a highly competitive space with its product candidate, cretostimogene grenadenorepvec, and the upcoming potential catalysts may not be sufficient for its success. Additionally, the company's focus on durability rather than response-driven outcomes may not be enough to differentiate itself from other late-stage biopharmaceutical companies. The potential upside from earlier-line opportunities and its differentiated ability to establish long-term immunity may not be enough to outweigh the risks associated with defending market exclusivity and potential challenges to its IP protection.